Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Fahrleitner, A; Prenner, G; Leb, G; Tscheliessnigg, KH; Piswanger-Sölkner, C; Obermayer-Pietsch, B; Portugaller, HR; Berghold, A; Dobnig, H.
Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
Bone. 2003; 32(1):96-106 Doi: 10.1016%2FS8756-3282%2802%2900926-2
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Führende Autor*innen der Med Uni Graz
Dobnig Harald
Fahrleitner-Pammer Astrid
Co-Autor*innen der Med Uni Graz
Berghold Andrea
Lipp-Solkner Claudia
Obermayer-Pietsch Barbara
Portugaller Rupert
Prenner Günther
Tscheliessnigg Karlheinz
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Osteoprotegerin (OPG) is an antiresorptive cytokine and a key regulator of osteoclastogenesis and activity. Since OPG is downregulated by glucocorticoids and cyclosporine A in vitro we examined whether immunosuppressive therapy would play a role in the development of transplantation osteoporosis. We enrolled 57 cardiac transplant recipients (median time since transplantation, 3.2 years (1.1-11.5 years)) in this cross-sectional study. Standardized spinal X-rays as well as hip bone density measurements were performed in all patients. Serum OPG was determined using a commercially available ELISA. Vertebral fractures were present in 56% of the patients. Bone densities of all femoral neck subregions were correlated to serum OPG concentrations (r values between 0.40 and 0.48, all P < 0.005). Multiple regression analysis revealed OPG levels to be independently correlated to femoral neck Z scores (r = 0.49, P = 0.002). After adjustment for age, BMI, neck Z score, renal function, and months since transplantation, serum OPG was the only significant predictor of prevalent vertebral fractures (P = 0.001). In a separate 6-month prospective study of 14 heart transplant recipients receiving calcium and vitamin D serum OPG levels fell by 41% (P = 0.0004) after 3 months and 47% (P = 0.0001) after 6 months following cardiac transplantation. Bone loss at the lumbar spine and femoral neck after 6 months was correlated to the decrease in serum OPG at 6 months (r = 0.82, P < 0.0001, and r = 0.60, P = 0.02, respectively) as well as 3 months after cardiac transplantation (r = 0.65, P = 0.01, and r = 0.69, P = 0.006, respectively). Serum OPG alone accounted for 67% of the variance of lumbar spine bone density changes over the first 6 months posttransplantation. We conclude that serum OPG levels decline consistently in all patients following initiation of immunosuppressive therapy and are independently correlated with changes in bone density. We hypothesize that OPG plays a major role in the development of transplantation osteoporosis.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Bone Density - drug effects
Chi-Square Distribution - drug effects
Cross-Sectional Studies - drug effects
Female - drug effects
Glycoproteins - blood
Heart Transplantation - adverse effects
Humans - adverse effects
Immunosuppressive Agents - adverse effects
Lumbar Vertebrae - drug effects
Male - drug effects
Middle Aged - drug effects
Osteoprotegerin - drug effects
Prospective Studies - drug effects
Receptors, Cytoplasmic and Nuclear - blood
Receptors, Tumor Necrosis Factor - blood
Regression Analysis - blood
Spinal Fractures - blood
Statistics, Nonparametric - blood

Find related publications in this database (Keywords)
osteoporosis
transplantation
immunosuppression
vertebral fractures
glucocorticoids
cylosporine A
© Med Uni Graz Impressum